Histopathologic characteristics in synchronous bilateral breast cancer patients: A nationwide Danish cohort study from 1999–2015

2018 ◽  
Vol 92 ◽  
pp. S157
Author(s):  
M.K. Mejdahl ◽  
N. Kroman ◽  
E. Balslev ◽  
J. Wohlfahrt ◽  
M. Melbye ◽  
...  
2019 ◽  
Vol 120 (7) ◽  
pp. 761-767 ◽  
Author(s):  
Mathias Kvist Mejdahl ◽  
Jan Wohlfahrt ◽  
Marianne Holm ◽  
Eva Balslev ◽  
Ann Søegaard Knoop ◽  
...  

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 561-561 ◽  
Author(s):  
A. Nichol ◽  
C. Bajdik ◽  
R. Yerushalmi ◽  
C. Speers ◽  
M. L'Esperance ◽  
...  

Breast Cancer ◽  
2021 ◽  
Author(s):  
Takamichi Yokoe ◽  
Sasagu Kurozumi ◽  
Kazuki Nozawa ◽  
Yukinori Ozaki ◽  
Tetsuyo Maeda ◽  
...  

Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are still in development with insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world treatment choice and efficacy of treatments after T-DM1 for HER2-positive metastatic breast cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female HER2-positive metastatic breast cancer patients whose post-T-DM1 treatment began between April 15, 2014 and December 31, 2018 were enrolled. The primary end point was the objective response rate (ORR) of post-T-DM1 treatments. Secondary end points included disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS). Results The median number of prior treatments of post-T-DM1 treatment was four. The types of post-T-DM1 treatments included (1) chemotherapy in combination with trastuzumab and pertuzumab (n = 102; 31.4%), (2) chemotherapy concomitant with trastuzumab (n = 78; 24.0%), (3), lapatinib with capecitabine (n = 63; 19.4%), and (4) others (n = 82; 25.2%). ORR was 22.8% [95% confidence interval (CI): 18.1–28.0], DCR = 66.6% (95% CI 60.8–72.0), median PFS = 6.1 months (95% CI 5.3–6.7), median TTF = 5.1 months (95% CI 4.4–5.6), and median OS = 23.7 months (95% CI 20.7–27.4). Conclusion The benefits of treatments after T-DM1 are limited. Further investigation of new treatment strategies beyond T-DM1 is awaited for HER2-positive metastatic breast cancer patients.


2017 ◽  
Vol 24 (4) ◽  
pp. 891-897
Author(s):  
Dominika Kozak ◽  
Iwona Głowacka-Mrotek ◽  
Tomasz Nowikiewicz ◽  
Zygmunt Siedlecki ◽  
Wojciech Hagner ◽  
...  

2021 ◽  
Vol 74 ◽  
pp. 102001
Author(s):  
Christiane E.S. Rudolph ◽  
Gerda Engholm ◽  
Ron Pritzkuleit ◽  
Hans H. Storm ◽  
Alexander Katalinic

Sign in / Sign up

Export Citation Format

Share Document